Concert Pharmaceuticals to Participate at Upcoming Investor Conferences
- The Stifel 2018 Healthcare Conference on November 14, 2018, at 2:00 p.m. ET in New York, NY;
- The Jefferies 2018 London Healthcare Conference on November 15, 2018, at 11:20 a.m. GMT in London; and
- The Global Mizuho Investor Conference on December 4, 2018 in New York.
A live webcast of the Stifel and Jefferies presentations may be accessed in the Investors section of the Company’s website at www.concertpharma.com. Please log on to the Concert website approximately 15 minutes prior to the scheduled webcast to ensure adequate time for any software downloads that may be required. A replay of the Stifel and Jefferies conference webcasts will be available on Concert’s website for two weeks following the presentations.
Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs. The Company’s approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert has a broad pipeline of innovative medicines targeting autoimmune and inflammatory diseases and central nervous systems (CNS) disorders. For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.
Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.
Concert Pharmaceuticals, Inc.
Justine Koenigsberg, 781-674-5284
Source: Concert Pharmaceuticals, Inc.